Healthcare Intelligence
Pharma Drug Discovery & R&D
Real-time intelligence, expert analysis, and verified research for the Pharma Drug Discovery & R&D industry. Stay ahead in 3 minutes a day.
Stay ahead of Pharma Drug Discovery & R&D in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
AtaiBeckley's EMP-01 Shows 49% Response Rate in Social Anxiety Disorder Trial
Phase 2a results demonstrate large symptom reductions with oral R-MDMA, no serious adverse events reported.
Read full articleMedicenna's MDNA113 Shows Superior Safety vs Competing PD-1 x IL-2 Therapies
First-in-class bifunctional demonstrates 30-fold wider therapeutic window in primate studies at AACR 2026.
Read full articleAmphista Reveals Structure of AMX-883 DCAF16 Degrader for AML at AACR
Lead BRD9 degrader shows picomolar potency, entering Phase I trials for acute myeloid leukemia in H2 2026.
Read full articleNovo Nordisk's Etavopivat Cuts Sickle Cell Crises by 27% in Phase 3
First-in-class PKR activator meets both primary endpoints, with 48.7% achieving hemoglobin response.
Read full articleAmazon Launches AI Tool for Code-Free Drug Discovery Workflows
Amazon Bio Discovery enables scientists to run complex computational workflows without programming expertise.
Read full articleAtaiBeckley's EMP-01 Shows 49% Response Rate in Social Anxiety Disorder Trial
Phase 2a results demonstrate large symptom reductions with oral R-MDMA, no serious adverse events reported.
Read full articleMedicenna's MDNA113 Shows Superior Safety vs Competing PD-1 x IL-2 Therapies
First-in-class bifunctional demonstrates 30-fold wider therapeutic window in primate studies at AACR 2026.
Read full articleAmphista Reveals Structure of AMX-883 DCAF16 Degrader for AML at AACR
Lead BRD9 degrader shows picomolar potency, entering Phase I trials for acute myeloid leukemia in H2 2026.
Read full articleNovo Nordisk's Etavopivat Cuts Sickle Cell Crises by 27% in Phase 3
First-in-class PKR activator meets both primary endpoints, with 48.7% achieving hemoglobin response.
Read full articleAmazon Launches AI Tool for Code-Free Drug Discovery Workflows
Amazon Bio Discovery enables scientists to run complex computational workflows without programming expertise.
Read full articleStay ahead of Pharma Drug Discovery & R&D in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.